文献速递肿瘤 PET/CT

[68Ga]Ga-PSMA-R2作为生化复发或转移性前列腺癌患者显像剂的安全性、剂量学与可行性

Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-03-03

PROfind(NCT03490032)是一项1/2期、开放标签、多中心研究,评估[68Ga]Ga-PSMA-R2在生化复发或转移性前列腺癌患者中的安全性、剂量学与可行性。每例给予3 MBq/kg(>150至≤250 MBq),1期纳入6例生化复发患者,2期纳入24例(生化复发与转移性各12例)。药物耐受良好,无药物相关治疗中出现的不良事件;主要吸收剂量位于膀胱壁(0.120 mGy/MBq)和肾脏(0.061 mGy/MBq),全身平均有效剂量为0.015 mSv/MBq(范围0.012-0.018)。

要点

  • 3 MBq/kg [68Ga]Ga-PSMA-R2耐受良好,无药物相关治疗中出现的不良事件。
  • 膀胱壁平均吸收剂量最高(0.120 mGy/MBq),其次为肾脏(0.061 mGy/MBq)。
  • 注射后1小时检出85个病灶(22例),2小时检出103个病灶(22例)。

核心结论

  • [68Ga]Ga-PSMA-R2耐受良好,无药物相关治疗中出现的不良事件。
  • 安全性与初步显像性能数据支持进一步开发[68Ga]Ga-PSMA-R2作为前列腺癌诊断剂。

研究设计与样本

  • PROfind(NCT03490032)为1/2期、开放标签、多中心研究,给予3 MBq/kg的[68Ga]Ga-PSMA-R2(>150至≤250 MBq)。
  • 1期纳入6例生化复发患者,2期纳入24例生化复发或转移性前列腺癌患者(各12例)。
  • 受试者接受基线常规影像(CT/MRI或骨扫描)和PET/CT,注射后20分钟至4小时行全身PET/CT显像序列。
  • 主要终点为安全性和耐受性;次要终点包括生物分布、潜在病灶识别、药代动力学和剂量学。
  • 潜在病灶由2个设盲专家小组识别,第3个小组成员评估已识别病灶。

主要发现

  • 报告13例治疗中出现的不良事件,包括1例严重不良事件(肠梗阻),与药物给药无关。
  • 所有不良事件均为轻或中度,且判定与[68Ga]Ga-PSMA-R2无关。
  • [68Ga]Ga-PSMA-R2血药峰浓度通常在注射后约5分钟出现,随后6小时内稳步下降。
  • 平均吸收辐射剂量最高为膀胱壁(0.120 mGy/MBq)和肾脏(0.061 mGy/MBq),其他器官平均吸收剂量均未超过0.020 mGy/MBq。
  • 唾液腺和泪腺平均吸收剂量分别为0.016和0.008 mGy/MBq;全身平均吸收剂量为0.014 mGy/MBq,平均全身有效剂量为0.015 mSv/MBq(范围0.012-0.018 mSv/MBq)。

关键数值与推荐

  • 给药剂量为3 MBq/kg的[68Ga]Ga-PSMA-R2(>150至≤250 MBq)。
  • 平均全身有效剂量为0.015 mSv/MBq(范围0.012-0.018 mSv/MBq)。
  • 膀胱壁和肾脏平均吸收剂量分别为0.120和0.061 mGy/MBq,其他器官均未超过0.020 mGy/MBq。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) is highly expressed in most prostate cancers (PCs). PET and CT imaging studies using 68Ga-labeled PSMA ligands demonstrated the specific localization of 68Ga in PC lesions and distant metastatic lesions. [68Ga]Ga-PSMA-R2 (68Ga-PSMA-R2) is a PSMA-targeted PET/CT radiotracer with potential diagnostic applications. Methods: PROfind (NCT03490032) was a phase 1/2, open-label, multicenter study of administration of 3 MBq/kg of 68Ga-PSMA-R2 (from >150 to ≤250 MBq) in patients with biochemical recurrence (BCR) or metastatic PC (mPC). Participants underwent baseline conventional imaging (CT/MRI or bone scan) and PET/CT. Whole-body PET/CT imaging sequences were obtained between 20 min and 4 h after injection. Primary endpoints were safety and tolerability; secondary endpoints included biodistribution, potential lesion identification, pharmacokinetics, and dosimetry. Potential lesions were identified by 2 masked expert panels; a third panel evaluated the identified lesions. Results: Six patients with BCR were enrolled into phase 1, and 24 patients with BCR or mPC (n = 12 each) into phase 2. Thirteen treatment-emergent adverse events were reported, including 1 serious adverse event (ileus), unrelated to drug administration. All adverse events were mild or moderate and deemed not related to 68Ga-PSMA-R2. Peak blood concentration of 68Ga-PSMA-R2 was typically observed approximately 5 min after injection, steadily decreasing over 6 h. Mean absorbed radiation dose was highest in the urinary bladder wall (0.120 mGy/MBq) and kidney (0.061 mGy/MBq). No other organ mean absorbed radiation dose exceeded 0.020 mGy/MBq. Mean absorbed radiation doses in the salivary and lacrimal glands were 0.016 and 0.008 mGy/MBq, respectively. Mean total body absorbed radiation dose was 0.014 mGy/MBq. Mean effective total body dose was 0.015 mSv/MBq (range, 0.012-0.018 mSv/MBq). 68Ga-PSMA-R2 PET/CT detected 85 lesions in 22 participants at 1 h after injection and 103 lesions in 22 participants at 2 h after injection. Conventional imaging detected 49 lesions in 8 participants with mPC but none in participants with BCR. Conclusion: 68Ga-PSMA-R2 was well tolerated, with no drug-related treatment-emergent adverse events. Safety and preliminary imaging performance data support further development of 68Ga-PSMA-R2 as a diagnostic agent in patients with PC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lindenberg L, Hope TA, Lin FI, et al. Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. J Nucl Med. 2025. PMID: 39915126. doi:10.2967/jnumed.124.268318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。